Q-omics provides the consensus-scored PRR13 profile across patient tissues and cancer cell-line models. PRR13 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PRR13 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PRR13 RNA expression shows 19,370 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KICH, and ACC as cancer lineages where PRR13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR13 survival associations across molecular data types. PRR13 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR13 RNA expression–survival associations across cancer types. High PRR13 expression shows unfavorable associations in LIHC, UVM, ESCA, LAML, KICH and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PRR13 RNA expression.
This table summarizes PRR13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR13 shows lower tumor expression in KICH and COAD and higher tumor expression in HNSC, LIHC, BRCA and STAD. The KICH box plot shows higher PRR13 RNA expression in normal versus tumor tissue (log2 FC = −1.497, t-test p < 0.001).
This table shows molecular features associated with PRR13 in patient tissues and cancer cell lines. In patient samples, PRR13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
